诺和诺德中国研发中心成立于1997年，是首家在华设立研发中心的跨国生物制药公司，位于北京中关村生命科学园，设施占地面积约18000平方米。诺和诺德中国研发中心依托于中国高速发展的生物医药科技带来的良性生态和人才优势，通过与药企、高校、科研院所和医院的广泛合作，旨在打造世界一流水准的医药研发中心。
目前，诺和诺德中国研发中心专注于研发治疗性蛋白及多肽类药物，拥有从早期药物靶点发现、验证，到候选药物分子筛选、优化，及临床前药代药理测试、评估的完善能力和丰富经验，是世界一流水准的医药研发中心。 研发中心参与公司在糖尿病、肥胖症和其它代谢相关的慢性疾病如非酒精性脂肪型肝炎、动脉粥样硬化、慢性肾病等领域众多新药研究项目，是诺和诺德全球研发体系的重要组成部分。
NNRCC, founded in 1997, takes pride in being the first research centre established by a multinational pharmaceutical company in China. Located in Zhongguancun Life Science Park, our state-of-the-art facilities cover 18,000 square metres. Tapping into the surrounding wealth of opportunities and talents in biomedical sciences, NNRCC strives to be a world class research centre in innovative drug discovery, forging collaborations among pharmaceutical companies, academic institutions, research entities, and hospitals.
With a focus on protein and peptide drug research, NNRCC has full capabilities and rich experiences in drug discovery, from early-stage target identification and validation, drug candidate selection and optimisation, to preclinical pharmacology (PK). Being an essential part of Novo Nordisk global R&D endeavours, NNRCC takes part in a large number of drug research projects in areas of diabetes, obesity and other chronic metabolic diseases, e.g. NASH, Atherosclerosis, CKD etc.
